2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R. Lyon, Julia Grapsa, Teresa López‐Fernández et al.|European Heart Journal|2022Cited by 2.7k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesJosé Luis Zamorano, Thomas Suter, Patrizio Lancellotti et al.|European Heart Journal|2016Cited by 2.5k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice GuidelinesJosé Luis Zamorano, Stephan Windecker, Dania Mohty et al.|European Journal of Heart Failure|2016Cited by 1.8k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Daniel J. Lenihan, Teresa López‐Fernández et al.|European Journal of Heart Failure|2020Cited by 767
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Peter Valent, Daniel J. Lenihan et al.|European Heart Journal|2021Cited by 589